Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRM-XRT
- Development stage
- Preclinical
- Lead developer
- Zylem Biosciences
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
MRM-XRT is a preclinical-stage gold nanoparticle-based radiation sensitizer developed by Zylem Biosciences. It is specifically designed to treat radiation-resistant prostate cancer, with potential expansion to other solid tumor types. The therapeutic approach utilizes gold nanoparticles to enhance the local effects of radiotherapy by increasing the absorption of ionizing radiation within the tumor microenvironment. The mechanism of action involves targeting glutathione peroxidase 4 (GPX4) and scavenger receptor class B member 1 (SR-B1), which are key regulators of lipid peroxidation and ferroptosis. By inhibiting these targets, MRM-XRT aims to sensitize cancer cells to radiation-induced oxidative stress and overcome common resistance mechanisms in advanced prostate cancer.
- Other names
- MRM-XRT
02
Targets
GPX4 (Glutathione peroxidase 4)SCARB1 (Scavenger receptor class B member 1)
Beyond the preview
Go deeper on MRM-XRT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRM-XRT.